You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Progressive spinal cord atrophy in manifest and premanifest Huntington’s disease

https://doi.org/10.1136/jnnp-2016-315000

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors WW: study concept and design, drafting and revising of manuscript, acquisition of data, statistical analysis, analysis and interpretation of data.

      BB: acquisition of data, statistical analysis, analysis and interpretation of data, drafting/revising the manuscript for content.

      RH: drafting/revising the manuscript for content, contribution of vital tools.

      RG: contributed to the design of the study, drafting/revising the manuscript for content.

      CS: drafting/revising the manuscript for content, study supervision or co-ordination.

      CL: study concept and design, drafting and revising of manuscript, drafting/revising the manuscript for content, study supervision, analysis and interpretation of data.

      All authors gave final approval of the version to be published.

    • Competing interests RG has received honoraria, consultant fees or other support from Baxter, Bayer Schering, Biogen Idec, CLB, Behring, Genzyme, Merck Serono, Novartis, Talecris, Teva and Wyeth. CS reports grants from Teva Endowed Professorship, grants from 'Cure Huntington's Disease Initiative´ (CHDI), grants from Biogen, personal fees from Temmler Pharma GmbH & Co. KG, personal fees from Desitin Arzneimittel GmbH, outside the submitted work; and CS received institutional compensation and/or travel or accommodation payments in the context of the ENROLL-Study (CHDI), Registry-Study of the Euro-HD-Network, in the context of the MitoNet-study, the ACR16-Study (Neurosearch), the AFQ-Study (Novartis), the Selisistat-Studies (Siena Biotech), the PRIDE-HD- and LEGATO-HD-Study (TEVA), the Amaryllis-Study (Pfizer) and in context of the IONIS 443139-CS1 Study. CL has received consulting and speaker's honoraria from BiogenIdec, Bayer Schering, Novartis, Sanofi, Genzyme and TEVA, and has received research scientific grant support from Bayer Schering, TEVA and MerckSerono. He holds an endowed professorship supported by the Novartis Foundation.

    • Patient consent Obtained.

    • Ethics approval Ethics Committee of the Medical Faculty Ruhr-University Bochum

    • Provenance and peer review Not commissioned; externally peer reviewed.